| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
| Targets |
4-Bromo-2-hydroxypyridine is an intermediate used to synthesize M1 muscarinic acetylcholine receptor (M1 mAChR) positive allosteric modulators. It is also used as a reagent to synthesize trans-3,4'-bispyridinylethylenes, compounds that act as inhibitors of protein kinase B for cancer treatment. It has been shown to have genotoxic activity and can inhibit DNA synthesis.
|
|---|---|
| ln Vitro |
In vitro, 4-bromo-2-hydroxypyridine is used as a chemical intermediate. It is used to synthesize M1 mAChR positive allosteric modulators for research on Alzheimer's disease and schizophrenia. It is also used to synthesize protein kinase B inhibitors for cancer research. Its genotoxic activity has been demonstrated in vitro.
|
| ln Vivo |
In vivo activity data for 4-bromo-2-hydroxypyridine itself are not available, as the compound is an intermediate used for synthesis. Rather, it is a precursor used in the synthesis of M1 mAChR modulators and kinase inhibitors that are subsequently evaluated in animal models.
|
| Enzyme Assay |
For in vitro chemical synthesis, 4-bromo-2-hydroxypyridine is used as a building block. The bromine atom can be used for cross-coupling reactions, and the hydroxyl group can be used for further derivatization. Standard protocols involve reacting the compound with appropriate reagents to introduce various substituents for the synthesis of target molecules.
|
| Cell Assay |
For in vitro cell-based experiments, 4-bromo-2-hydroxypyridine is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and receptor binding assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO.
|
| Animal Protocol |
In vivo animal studies using 4-bromo-2-hydroxypyridine are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For M1 mAChR modulators or kinase inhibitors derived from this building block, efficacy studies would typically be performed in mouse models of Alzheimer's disease, schizophrenia, or cancer.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-bromo-2-hydroxypyridine as a standalone compound are not characterized in the literature. The compound is a solid and should be stored under appropriate conditions.
|
| Toxicity/Toxicokinetics |
4-Bromo-2-hydroxypyridine is a research chemical and should be handled with appropriate laboratory safety precautions. As a brominated compound, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications.
|
| Additional Infomation |
4-Bromo-2-hydroxypyridine (CAS 36953-37-4) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as an intermediate for synthesizing M1 mAChR positive allosteric modulators for Alzheimer's and schizophrenia research, and as a reagent for synthesizing protein kinase B inhibitors for cancer research.
|
| Molecular Formula |
C5H4BRNO
|
|---|---|
| Molecular Weight |
174.00
|
| Exact Mass |
172.947
|
| CAS # |
36953-37-4
|
| PubChem CID |
817115
|
| Appearance |
White to light brown solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
346.4±22.0 °C at 760 mmHg
|
| Melting Point |
186ºC
|
| Flash Point |
163.3±22.3 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.614
|
| LogP |
0.55
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
171
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C=C(Br)C=CN1
|
| InChi Key |
SSLMGOKTIUIZLY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H4BrNO/c6-4-1-2-7-5(8)3-4/h1-3H,(H,7,8)
|
| Chemical Name |
4-bromo-1H-pyridin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (574.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.7471 mL | 28.7356 mL | 57.4713 mL | |
| 5 mM | 1.1494 mL | 5.7471 mL | 11.4943 mL | |
| 10 mM | 0.5747 mL | 2.8736 mL | 5.7471 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
